Nature Communications (Jun 2021)
AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines
- Liyang Zhang,
- John A. Zuris,
- Ramya Viswanathan,
- Jasmine N. Edelstein,
- Rolf Turk,
- Bernice Thommandru,
- H. Tomas Rube,
- Steve E. Glenn,
- Michael A. Collingwood,
- Nicole M. Bode,
- Sarah F. Beaudoin,
- Swarali Lele,
- Sean N. Scott,
- Kevin M. Wasko,
- Steven Sexton,
- Christopher M. Borges,
- Mollie S. Schubert,
- Gavin L. Kurgan,
- Matthew S. McNeill,
- Cecilia A. Fernandez,
- Vic E. Myer,
- Richard A. Morgan,
- Mark A. Behlke,
- Christopher A. Vakulskas
Affiliations
- Liyang Zhang
- Integrated DNA Technologies, Inc
- John A. Zuris
- Editas Medicine Inc, 11 Hurley St
- Ramya Viswanathan
- Editas Medicine Inc, 11 Hurley St
- Jasmine N. Edelstein
- Editas Medicine Inc, 11 Hurley St
- Rolf Turk
- Integrated DNA Technologies, Inc
- Bernice Thommandru
- Integrated DNA Technologies, Inc
- H. Tomas Rube
- University of California - Merced, 5200 Lake Rd
- Steve E. Glenn
- Integrated DNA Technologies, Inc
- Michael A. Collingwood
- Integrated DNA Technologies, Inc
- Nicole M. Bode
- Integrated DNA Technologies, Inc
- Sarah F. Beaudoin
- Integrated DNA Technologies, Inc
- Swarali Lele
- Editas Medicine Inc, 11 Hurley St
- Sean N. Scott
- Editas Medicine Inc, 11 Hurley St
- Kevin M. Wasko
- Editas Medicine Inc, 11 Hurley St
- Steven Sexton
- Editas Medicine Inc, 11 Hurley St
- Christopher M. Borges
- Editas Medicine Inc, 11 Hurley St
- Mollie S. Schubert
- Integrated DNA Technologies, Inc
- Gavin L. Kurgan
- Integrated DNA Technologies, Inc
- Matthew S. McNeill
- Integrated DNA Technologies, Inc
- Cecilia A. Fernandez
- Editas Medicine Inc, 11 Hurley St
- Vic E. Myer
- Editas Medicine Inc, 11 Hurley St
- Richard A. Morgan
- Editas Medicine Inc, 11 Hurley St
- Mark A. Behlke
- Integrated DNA Technologies, Inc
- Christopher A. Vakulskas
- Integrated DNA Technologies, Inc
- DOI
- https://doi.org/10.1038/s41467-021-24017-8
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 15
Abstract
The utility of AsCas12a can be limited to poor editing efficiency. Here the authors identify a variant, “AsCas12a Ultra”, that has high on-target specificity demonstrated through editing of clinically relevant T cell genes.
